DR REDDYS LABORATORIES SHARE PRICE

Dr Reddy’s Laboratories Ltd. is an Indian multinational pharmaceutical company. It manufactures and markets a wide range of pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, and biologics. It was incorporated in 1984 with its headquarters in Hyderabad, Telangana. The company’s total income for the quarter ended June 2022 was Rs HYPERLINK "https://economictimes.indiatimes.com/dr-reddys-laboratories-ltd/stocks/companyid-13841.cms" 6,086.80 crore. On 5 August 2022, its market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/drreddyslaboratories/DRL" 69,190 crore.
The company is listed on the Bombay Stock Exchange with the code 500124 and on the National Stock Exchange with the code DRREDDY. It is also listed on the MCX Stock Exchange.
Dr Reddy’s Laboratories Ltd. has research and development centres and manufacturing facilities in 66 countries, with an employee strength of more than 24,000. For FY 2021-2022, the company’s profit after tax was Rs 2,182.50 crore, up 11.83% from FY 2020-2021. Its total assets for FY 2021-2022 stood at Rs 29,746.90 crore.
The company’s shareholding pattern on 30 June 2022 indicated a promoter stake of 26.71%, foreign institutional investor stake of 25.87%, domestic institutional investor stake of 25.19%, and public stake of 21.96%. The promoters have decreased holdings from 26.72% to 26.71% in the June 2022 quarter, while the mutual fund holdings have increased from 14.12% to 14.21%.
The company’s chairman is Mr K Satish Reddy. The co-chairman and managing director is Mr G V Prasad. The other board members include Mr Leo Puri, Ms Shikha Sharma, Dr Bruce L A Carter, Mr Allan Oberman, Mr Prasad R Menon, Ms Kalpana Morparia, and Mr Sridar Iyengar. The company’s auditors are S R Batliboi & Associates LLP.
On 5 August 2022, Dr Reddy’s Laboratories Ltd.’s share price on BSE closed at Rs 4154. Its NSE share price closed at Rs 4,156.85. The company’s 52-week high share price was Rs 5,077, and the 52-week low was Rs 3,654.
As of July 2022, the company’s mutual fund holdings included Franklin India Pension Plan, Aditya Birla SL Equity Hybrid ‘95 Fund, Franklin India Debt Hybrid Fund, and ICICI Prudential Regular Savings Fund with 1.04%, 0.79%, 0.62%, and 0.60% stake, respectively.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Dr Reddys Laboratories share price as on 19 Apr 2025 is Rs. 1163.6. Over the past 6 months, the Dr Reddys Laboratories share price has decreased by 13.31% and in the last one year, it has decreased by 3.84%. The 52-week low for Dr Reddys Laboratories share price was Rs. 1020 and 52-week high was Rs. 1421.49.

Dr Reddy’s Laboratories Ltd. is an Indian multinational pharmaceutical company. It manufactures and markets a wide range of pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, and biologics. It was incorporated in 1984 with its headquarters in Hyderabad, Telangana. The company’s total income for the quarter ended June 2022 was Rs HYPERLINK "https://economictimes.indiatimes.com/dr-reddys-laboratories-ltd/stocks/companyid-13841.cms" 6,086.80 crore. On 5 August 2022, its market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/drreddyslaboratories/DRL" 69,190 crore.
The company is listed on the Bombay Stock Exchange with the code 500124 and on the National Stock Exchange with the code DRREDDY. It is also listed on the MCX Stock Exchange.
Dr Reddy’s Laboratories Ltd. has research and development centres and manufacturing facilities in 66 countries, with an employee strength of more than 24,000. For FY 2021-2022, the company’s profit after tax was Rs 2,182.50 crore, up 11.83% from FY 2020-2021. Its total assets for FY 2021-2022 stood at Rs 29,746.90 crore.
The company’s shareholding pattern on 30 June 2022 indicated a promoter stake of 26.71%, foreign institutional investor stake of 25.87%, domestic institutional investor stake of 25.19%, and public stake of 21.96%. The promoters have decreased holdings from 26.72% to 26.71% in the June 2022 quarter, while the mutual fund holdings have increased from 14.12% to 14.21%.
The company’s chairman is Mr K Satish Reddy. The co-chairman and managing director is Mr G V Prasad. The other board members include Mr Leo Puri, Ms Shikha Sharma, Dr Bruce L A Carter, Mr Allan Oberman, Mr Prasad R Menon, Ms Kalpana Morparia, and Mr Sridar Iyengar. The company’s auditors are S R Batliboi & Associates LLP.
On 5 August 2022, Dr Reddy’s Laboratories Ltd.’s share price on BSE closed at Rs 4154. Its NSE share price closed at Rs 4,156.85. The company’s 52-week high share price was Rs 5,077, and the 52-week low was Rs 3,654.
As of July 2022, the company’s mutual fund holdings included Franklin India Pension Plan, Aditya Birla SL Equity Hybrid ‘95 Fund, Franklin India Debt Hybrid Fund, and ICICI Prudential Regular Savings Fund with 1.04%, 0.79%, 0.62%, and 0.60% stake, respectively.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Dr Reddys Laboratories share price as on 19 Apr 2025 is Rs. 1163.6. Over the past 6 months, the Dr Reddys Laboratories share price has decreased by 13.31% and in the last one year, it has decreased by 3.84%. The 52-week low for Dr Reddys Laboratories share price was Rs. 1020 and 52-week high was Rs. 1421.49.